Publication: Multidrug resistant Escherichia coli isolated at National Public Health Laboratory, Nepal
| creativeworkseries.issn | 1999-6217 | |
| dc.contributor.author | Acharya, Jyoti | |
| dc.contributor.author | Shrestha, Anjana | |
| dc.contributor.author | Rijal, Nisha | |
| dc.contributor.author | Jha, Runa | |
| dc.contributor.author | Rijal, Komal Raj | |
| dc.contributor.author | Sharma, Supriya | |
| dc.contributor.author | Raj Banjara, Megha | |
| dc.contributor.author | Ghimire, Prakash | |
| dc.date.accessioned | 2025-07-11T05:57:51Z | |
| dc.date.available | 2025-07-11T05:57:51Z | |
| dc.date.issued | 2025 | |
| dc.description | Author Biography Nisha Rijal, National Public Health Laboratory, Tripura Marg, Teku, Kathmandu, Nepal. Microbiologist working in AMR surveillance at Microbiology Laboratory. | |
| dc.description.abstract | Background: Antimicrobial resistance in Escherichia coli is mostly associated with ß-lactamases and carbapenemases enzyme production resulting in treatment challenges. This study was conducted with the aim to detect and characterize antimicrobial resistance in E. coli isolates. Methods: A cross-sectional study was conducted during 2018-2022, at National Public Health Laboratory where the clinical specimens (24636) received were processed for identification and characterization of antimicrobial resistance following conventional & advanced methods. Antibiotic susceptibility tests were performed by Modified Kirby Bauer disc diffusion and Minimum inhibitory concentrations using VITEK2 compact (Biomeriux). The isolates were tested for extended-spectrum ?-lactamases and Carbapenemase production following Clinical Laboratory Standards Institute guidelines. Results: Bacterial growth was observed in 9% (2166/24636) of the specimens, of which 44% (959) were E. coli. Among the 959 E. coli isolates, 320 were reconfirmed with VITEK-MS (Biomeriux). Phenotypic multi-drug resistance was observed in 75% (240/320) of the isolates with 62% (197/320) extended-spectrum ?-lactamases, 12% (39/320) AmpC-ß-lactamase, 10% (31/320) serine carbapenemases and 7% (22/320) Metallo-ß-lactamase while 3% (9/320) produced three types of enzymes. The extended-spectrum-?-lactamase producing E. coli were sensitive to Tigecycline (100%), Amikacin (92%), Imipenem (87%), and Meropenem (84%). Carbapenemase producers were sensitive to Tigecycline (100%), with 61% to Amikacin. Extensive-drug resistance was observed in 2% (7/320) of the isolates, with Colistin resistance in one. Conclusions: The findings highlight alarmingly high antimicrobial resistance in E. coli posing significant challenges in treatment. Early detection of multi-drug resistant isolates in healthcare settings is crucial to combat antimicrobial resistance. Keywords: ?-lactamase; carbapenemases; extensive-drug resistance; metallo-ß-lactamase; multidrug resistance | |
| dc.identifier | https://doi.org/10.33314/jnhrc.v23i01.5067 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14572/93 | |
| dc.language.iso | en_US | |
| dc.title | Multidrug resistant Escherichia coli isolated at National Public Health Laboratory, Nepal | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.article.type | Original Article | |
| relation.isJournalIssueOfPublication | 710a5a58-3a9b-4cdc-9898-5e7769f7ec25 | |
| relation.isJournalIssueOfPublication.latestForDiscovery | 710a5a58-3a9b-4cdc-9898-5e7769f7ec25 | |
| relation.isJournalOfPublication | 40bd2739-8b19-447c-be60-723a1bdd1dcd |